Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $38.57 Consensus Price Target from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $38.57.

A number of research firms have weighed in on ZNTL. HC Wainwright reiterated a “buy” rating and set a $46.00 target price on shares of Zentalis Pharmaceuticals in a report on Wednesday, February 28th. Wedbush upped their price target on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th.

Insider Transactions at Zentalis Pharmaceuticals

In related news, CFO Melissa B. Epperly sold 2,573 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total transaction of $29,435.12. Following the completion of the transaction, the chief financial officer now owns 451,449 shares of the company’s stock, valued at approximately $5,164,576.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Eventide Asset Management LLC boosted its stake in Zentalis Pharmaceuticals by 47.9% in the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock worth $175,134,000 after purchasing an additional 3,745,936 shares in the last quarter. Decheng Capital LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $31,809,000. Vanguard Group Inc. increased its position in shares of Zentalis Pharmaceuticals by 6.2% during the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock valued at $105,047,000 after acquiring an additional 307,490 shares in the last quarter. Federated Hermes Inc. raised its holdings in Zentalis Pharmaceuticals by 10.9% in the 4th quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock worth $32,733,000 after acquiring an additional 212,872 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its position in Zentalis Pharmaceuticals by 79.4% in the 4th quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock valued at $5,456,000 after acquiring an additional 159,439 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $13.00 on Thursday. The business has a 50 day simple moving average of $14.12 and a two-hundred day simple moving average of $14.00. The firm has a market capitalization of $922.48 million, a price-to-earnings ratio of -2.86 and a beta of 1.73. Zentalis Pharmaceuticals has a one year low of $9.56 and a one year high of $31.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.09. As a group, sell-side analysts expect that Zentalis Pharmaceuticals will post -3.72 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.